Serious bacterial infections are a major cause of death in hospitals and healthcare settings. Drug resistance makes these infections more difficult to treat. In turn, surgical procedures and chemotherapy carry greater risk. Global action to develop new treatments for drug-resistant infections can prevent the next global health emergency.
A Q&A on the collaboration between GARDP and Venatorx Pharmaceuticals to accelerate the development of cefepime-taniborbactam as a treatment for drug-resistant hospital infections.
GARDP is working on a novel antibiotic called zoliflodacin, the only drug being developed specifically to treat gonorrhoea. The treatment is currently being evaluated in a global phase 3 trial. One of the sites where the drug is being trialled is in the US city of Birmingham, Alabama.
The development of antibiotics transformed our world, saving millions of lives and radically improving our health. Now, time with these drugs is running out. GARDP is calling on the world to raise €500 million to support the delivery of five new treatments by 2025 to tackle the drug-resistant infections that pose the greatest threat to global health and economic security.
Globally the infection rate of gonorrhoea is increasing, with 87 million new cases each year. Gonorrhoea has progressively developed resistance to globally recommended treatments and has been identified by the WHO as among a family of drug-resistant priority pathogens posing the greatest threat to health. The Global Antibiotic Research and Development Partnership (GARDP) is working […]